Celsion Corporation (CLSN): Price and Financial Metrics


Celsion Corporation (CLSN): $2.42

0.06 (+2.54%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CLSN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CLSN POWR Grades


  • Sentiment is the dimension where CLSN ranks best; there it ranks ahead of 87.35% of US stocks.
  • CLSN's strongest trending metric is Growth; it's been moving down over the last 105 days.
  • CLSN's current lowest rank is in the Momentum metric (where it is better than 4.12% of US stocks).

CLSN Stock Summary

  • With a price/sales ratio of 60.01, Celsion CORP has a higher such ratio than 96.57% of stocks in our set.
  • In terms of volatility of its share price, CLSN is more volatile than 99.83% of stocks we're observing.
  • Celsion CORP's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -156.4%, greater than the shareholder yield of only 2.1% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Celsion CORP, a group of peers worth examining would be HTBX, ABEO, HRTX, NVCN, and QUIK.
  • Visit CLSN's SEC page to see the company's official filings. To visit the company's web site, go to www.celsion.com.

CLSN Valuation Summary

  • In comparison to the median Healthcare stock, CLSN's price/sales ratio is 4731.58% higher, now standing at 183.6.
  • Over the past 243 months, CLSN's price/sales ratio has gone down 15949.7.
  • CLSN's EV/EBIT ratio has moved up 4.2 over the prior 243 months.

Below are key valuation metrics over time for CLSN.

Stock Date P/S P/B P/E EV/EBIT
CLSN 2021-08-31 183.6 1.4 -4.1 -3.1
CLSN 2021-08-30 178.4 1.4 -4.0 -3.0
CLSN 2021-08-27 178.4 1.4 -4.0 -3.0
CLSN 2021-08-26 180.0 1.4 -4.1 -3.0
CLSN 2021-08-25 181.8 1.4 -4.1 -3.1
CLSN 2021-08-24 176.6 1.4 -4.0 -3.0

CLSN Growth Metrics

    Its 5 year cash and equivalents growth rate is now at -59.85%.
  • Its 5 year net cashflow from operations growth rate is now at -0.3%.
  • Its year over year net cashflow from operations growth rate is now at 21.92%.
CLSN's revenue has moved down $0 over the prior 33 months.

The table below shows CLSN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 0.5 -14.86713 -19.5601
2021-06-30 0.5 -15.0448 -22.22115
2021-03-31 0.5 -15.38047 -22.11569
2020-12-31 0.5 -15.61868 -21.48356
2020-09-30 0.5 -17.50368 -21.57417
2020-06-30 0.5 -18.02039 -18.97938

CLSN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CLSN has a Quality Grade of C, ranking ahead of 25.08% of graded US stocks.
  • CLSN's asset turnover comes in at 0.009 -- ranking 397th of 682 Pharmaceutical Products stocks.
  • AWH, DRRX, and KDMN are the stocks whose asset turnover ratios are most correlated with CLSN.

The table below shows CLSN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.009 1 -0.745
2021-03-31 0.010 1 -0.993
2020-12-31 0.012 1 -0.936
2020-09-30 0.012 1 -0.804
2020-06-30 0.012 1 -0.624
2020-03-31 0.012 1 -0.569

CLSN Price Target

For more insight on analysts targets of CLSN, see our CLSN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $3.00 Average Broker Recommendation 1.75 (Moderate Buy)

CLSN Stock Price Chart Interactive Chart >

Price chart for CLSN

CLSN Price/Volume Stats

Current price $2.42 52-week high $23.25
Prev. close $2.36 52-week low $2.23
Day low $2.31 Volume 42,600
Day high $2.46 Avg. volume 218,136
50-day MA $3.63 Dividend yield N/A
200-day MA $8.93 Market Cap 17.18M

Celsion Corporation (CLSN) Company Bio


Celsion Corporation focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company was founded in 1982 and is based in Lawrenceville, New Jersey.


CLSN Latest News Stream


Event/Time News Detail
Loading, please wait...

CLSN Latest Social Stream


Loading social stream, please wait...

View Full CLSN Social Stream

Latest CLSN News From Around the Web

Below are the latest news stories about Celsion CORP that investors may wish to consider to help them evaluate CLSN as an investment opportunity.

Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

OVATION 2 Study is Over 75% Enrolled; Full Enrollment Expected by Mid-2022 Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month Period LAWRENCEVILLE, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that following a pre-planned interim safety review of 81 as treated patients randomized in the Phase

Yahoo | February 17, 2022

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Preclinical results demonstrate safe and efficient immune response with vaccine development showing promise of neutralizing activity for a range of variants LAWRENCEVILLE, N.J., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation DNA-based vaccines, announces it has engaged BIOQUAL, Inc., a preclinical testing contract research organization, to conduct a non-human primate (NHP) challenge

Yahoo | January 31, 2022

Celsion prices and closes preferred stock offering (NASDAQ:CLSN)

Celsion (CLSN) has priced and closed its registered direct offering of convertible redeemable preferred stock.The company entered into a securities purchase agreement with

Seeking Alpha | January 13, 2022

Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock

LAWRENCEVILLE, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced the closing of its previously announced registered direct offering with certain institutional investors to purchase 50,000 shares of Series A convertible redeemable preferred stock and 50,000 shares of Series B convertible redeemable preferred stock. Each share of Series A and Series B pref

Yahoo | January 13, 2022

State Street Corp Makes New Investment in Celsion Co. (NASDAQ:CLSN)

State Street Corp bought a new position in shares of Celsion Co. (NASDAQ:CLSN) in the 2nd quarter, Holdings Channel reports. The institutional investor bought 214,568 shares of the biotechnology companys stock, valued at approximately $273,000. A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the []

Transcript Daily | December 9, 2021

Read More 'CLSN' Stories Here

CLSN Price Returns

1-mo -17.69%
3-mo -56.99%
6-mo -79.05%
1-year -86.33%
3-year -92.24%
5-year -94.99%
YTD -70.12%
2021 -24.05%
2020 -58.42%
2019 21.28%
2018 -47.39%
2017 -36.19%

Continue Researching CLSN

Want to see what other sources are saying about Celsion CORP's financials and stock price? Try the links below:

Celsion CORP (CLSN) Stock Price | Nasdaq
Celsion CORP (CLSN) Stock Quote, History and News - Yahoo Finance
Celsion CORP (CLSN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4768 seconds.